Murthy Hemant, Iqbal Madiha, Chavez Julio C, Kharfan-Dabaja Mohamed A
Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA.
Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
Immunotargets Ther. 2019 Oct 29;8:43-52. doi: 10.2147/ITT.S202015. eCollection 2019.
Chimeric antigen receptor T cell (CART) therapy represents a novel and a paradigm-shifting approach to treating cancer. Recent clinical successes have widened the applicability of CD19 CART cells for the treatment of relapsed/refractory B-cell NHL, namely tisagenleclucel and axicabtagene ciloleucel. Tisagenleclucel is also approved for relapsed and/or refractory B-ALL up to age 25. CART therapy is associated with unique and potentially life-threatening toxicities, notably cytokine release syndrome (CRS). A better understanding of the pathogenesis of CRS is crucial to ensure proper management. In this review, CRS definitions, profiles, risk factors and grading systems are discussed. Finally, current and novel investigational approaches and therapies for CRS are summarized.
嵌合抗原受体T细胞（CART）疗法是一种治疗癌症的全新且具有范式转变意义的方法。近期的临床成功扩大了CD19 CART细胞在治疗复发/难治性B细胞非霍奇金淋巴瘤（NHL）方面的适用性，即tisagenleclucel和axi-cabtagene ciloleucel。Tisagenleclucel也被批准用于治疗25岁及以下复发和/或难治性B淋巴细胞白血病（B-ALL）。CART疗法伴随着独特且可能危及生命的毒性，尤其是细胞因子释放综合征（CRS）。更好地理解CRS发病机制对于确保恰当管理至关重要。在本综述中，将讨论CRS的定义、特征、危险因素和分级系统。最后，总结了CRS目前的和新的研究方法及治疗手段。
